ID   NCC-UPS4-C1
AC   CVCL_B6KI
DR   cancercelllines; CVCL_B6KI
DR   Wikidata; Q112129416
RX   PubMed=35118583;
WW   https://en.cellline.jp/product/ncc-ups4-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 76 hours (PubMed=35118583).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Heterozygous (PubMed=35118583).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (PubMed=35118583).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Right knee, hypodermis; UBERON=UBERON_0001465+UBERON_0002072.
ST   Source(s): PubMed=35118583
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,13
ST   D16S539: 12
ST   D21S11: 29,32.2
ST   D5S818: 10,11
ST   D7S820: 11
ST   TH01: 7,8
ST   TPOX: 8,9
ST   vWA: 14,19
DI   NCIt; C3476; Li-Fraumeni syndrome
DI   NCIt; C4247; Undifferentiated pleomorphic sarcoma
DI   ORDO; Orphanet_524; Li-Fraumeni syndrome
DI   ORDO; Orphanet_2023; Undifferentiated pleomorphic sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 30-01-24; Version: 6
//
RX   PubMed=35118583; DOI=10.1007/s13577-022-00671-y;
RA   Ono T., Yoshimatsu Y., Noguchi R., Sin Y., Tsuchiya R., Akiyama T.,
RA   Sugaya J., Fukushima S., Kojima N., Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and characterization of NCC-UPS4-C1: a novel cell line
RT   of undifferentiated pleomorphic sarcoma from a patient with
RT   Li-Fraumeni syndrome.";
RL   Hum. Cell 35:756-766(2022).
//